Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7781643 | Carbohydrate Polymers | 2018 | 37 Pages |
Abstract
Combination therapy with chemotherapeutics is attracting increasing attention as an important treatment option for hepatocellular carcinoma (HCC) due to its complex pathological characteristics. In this study, as a new therapy strategy, combination treatment of LEP-2a (a non-toxic polysaccharide from Lachnum sp.) with cyclophosphamide (CTX) was investigated. Results showed that combination treatment with LEP-2a and CTX processed a significantly synergistic anti-tumor effect in H22 tumor-bearing mice through Fas/FasL mediated caspase-dependent death pathway and mitochondria apoptosis pathway. Moreover, our study indicated that LEP-2a played a crucial role in enhancement of immune response, inhibition of tumor angiogenesis and down-regulation of survival associated proteins. Notably, side effects induced by CTX were relieved after LEP-2a treatment. These results support the conception that LEP-2a has the potential as an ideal adjuvant agent for a more effective combination therapy with CTX against HCC.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Shuai Zong, Jinglei Li, Liu Yang, Qianli Huang, Ziyang Ye, Guohua Hou, Ming Ye,